Fig. 2

In the upper part of panel, representative images of the baseline values of fibrous cap thickness (FCT) and lipid arch in SGLT2-I users (A, left part) vs. Non-SGLT2-I users (B, right part) patients. The lipid length was 8.46 ± 1.87 vs. 8.39 ± 1.89 mm (p > 0.05) in SGLT2-I users vs. Non-SGLT2-I users patients. The macrophage grade was 12.04 ± 2.29 vs. 12.07 ± 2.31 (p > 0.05) in SGLT2-I users vs. Non-SGLT2-I users patients. The representative images of coronary vessels (inferior part) are of the middle segment of left anterior descending artery (LAD), comparing the SGLT2-I users (C, left part) vs. Non-SGLT2-I users’ (D, right part) patients. The red circle evidences the intermediate and non-obstructive coronary stenosis (NOCS) LAD stenosis. In the lower part of the panel, representative images of follow-up end values of fibrous cap thickness (FCT) and lipid arch in SGLT2-I users (E, left upper part) vs. Non-SGLT2-I users patients (F, right upper part). The lipid length was 7.92 ± 1.89 vs. 7.79 ± 1.88 mm (p > 0.05) in SGLT2-I users vs. Non-SGLT2-I users patients. The macrophage grade was 7.24 ± 2.22 vs. 9.27 ± 2.56 (p < 0.05) in SGLT2-I users vs. Non-SGLT2-I users patients. The representative images of coronary vessels (inferior left and right part) is the middle segment of anterior descending artery, comparing the SGLT2-I users (G, left inferior part) vs. Non-SGLT2-I users’ (H, right inferior part) patients. The red circle evidences the intermediate and non obstructive coronary stenosis (NOCS) LAD stenosis. SGLT2-I sodium glucose transporter 2 inhibitors